Nicholas J. Short, MD, on the Future of ALL and Possibilities for Transplant in These Patients

News
Video

Short expanded on the future of acute lymphoblastic leukemia and transplantation necessity at the 2020 ASH Annual Meeting & Exposition.

In an interview with CancerNetwork®, Nicholas J. Short, MD, of the University of Texas MD Anderson Cancer Center, explained what’s coming next for the field of acute lymphoblastic leukemia (ALL) at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.

Transcription:

It’s important that we continue to optimize ALL regimens. And with all regimens, there is a risk of toxicity with intensive chemotherapy and with long durations of chemotherapy. It’s relatively rare in a very fit population, but there are still patients who get significant cytopenias, have major infections, or even die in remission because of the need for repetitive [therapy] cycles, at least with our current paradigms of chemotherapy. If there’s anything that we can do to identify patients who don’t need to continue with 2 to 3 years of maintenance therapy, that would be clinically important.

A big question in the field of ALL in general is, “which patients need transplant?” Obviously, transplant comes with significant morbidity and potential for mortality. If we can identify patients who don’t need a transplant in first remission, that would be important for improving long-term outcomes for these patients.

Recent Videos
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
Related Content